메뉴 건너뛰기




Volumn 37, Issue 3, 2017, Pages 341-346

Amantadine for antipsychotic-related weight gain: Meta-analysis of randomized placebo-controlled trials

Author keywords

Amantadine; Meta analysis; Schizophrenia; Weight gain

Indexed keywords

AMANTADINE; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; DOPAMINE RECEPTOR STIMULATING AGENT;

EID: 85017153004     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0000000000000598     Document Type: Article
Times cited : (9)

References (31)
  • 1
    • 54849381700 scopus 로고    scopus 로고
    • Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study
    • Daumit GL, Goff DC, Meyer JM, et al. Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study. Schizophr Res. 2008;105:175-187.
    • (2008) Schizophr Res. , vol.105 , pp. 175-187
    • Daumit, G.L.1    Goff, D.C.2    Meyer, J.M.3
  • 2
    • 26644445926 scopus 로고    scopus 로고
    • Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks andmortality: Results of a 10-year naturalistic study
    • Henderson DC, Nguyen DD, Copeland PM, et al. Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks andmortality: results of a 10-year naturalistic study. J Clin Psychiatry. 2005;66:1116-1121.
    • (2005) J Clin Psychiatry. , vol.66 , pp. 1116-1121
    • Henderson, D.C.1    Nguyen, D.D.2    Copeland, P.M.3
  • 3
    • 79952273080 scopus 로고    scopus 로고
    • Antipsychotics and metabolics in the post-CATIE era
    • Meyer JM. Antipsychotics and metabolics in the post-CATIE era. Curr Top Behav Neurosci. 2010;4:23-42.
    • (2010) Curr Top Behav Neurosci. , vol.4 , pp. 23-42
    • Meyer, J.M.1
  • 4
    • 84912541812 scopus 로고    scopus 로고
    • Pharmacological strategies to counteract antipsychotic-induced weight gain and metabolic adverse effects in schizophrenia: A systematic review and meta-analysis
    • Mizuno Y, Suzuki T, Nakagawa A, et al. Pharmacological strategies to counteract antipsychotic-induced weight gain and metabolic adverse effects in schizophrenia: A systematic review and meta-analysis. Schizophr Bull. 2014;40:1385-1403.
    • (2014) Schizophr Bull. , vol.40 , pp. 1385-1403
    • Mizuno, Y.1    Suzuki, T.2    Nakagawa, A.3
  • 5
    • 84883728317 scopus 로고    scopus 로고
    • Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder
    • Jarskog LF, Hamer RM, Catellier DJ, et al. Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder. Am J Psychiatry. 2013;170:1032-1040.
    • (2013) Am J Psychiatry. , vol.170 , pp. 1032-1040
    • Jarskog, L.F.1    Hamer, R.M.2    Catellier, D.J.3
  • 6
    • 84941282320 scopus 로고    scopus 로고
    • Metformin for weight gain and metabolic abnormalities associated with antipsychotic treatment: Meta-analysis of randomized placebo-controlled trials
    • ZhengW, Li XB, Tang YL, et al. Metformin for weight gain and metabolic abnormalities associated with antipsychotic treatment: meta-analysis of randomized placebo-controlled trials. J Clin Psychopharmacol. 2015;35: 499-509.
    • (2015) J Clin Psychopharmacol. , vol.35 , pp. 499-509
    • Zheng, W.1    Li, X.B.2    Tang, Y.L.3
  • 7
    • 84998166021 scopus 로고    scopus 로고
    • Amantadine for olanzapine-induced weight gain: A systematic review and meta-analysis of randomized placebo-controlled trials
    • Praharaj SK, Sharma PS. Amantadine for olanzapine-induced weight gain: A systematic review and meta-analysis of randomized placebo-controlled trials. Ther Adv Psychopharmacol. 2012;2:151-156.
    • (2012) Ther Adv Psychopharmacol. , vol.2 , pp. 151-156
    • Praharaj, S.K.1    Sharma, P.S.2
  • 8
    • 84880133046 scopus 로고    scopus 로고
    • NMDA receptor antagonists interventions in schizophrenia: Meta-analysis of randomized, placebo-controlled trials
    • Kishi T, Iwata N. NMDA receptor antagonists interventions in schizophrenia: Meta-analysis of randomized, placebo-controlled trials. J Psychiatr Res. 2013;47:1143-1149.
    • (2013) J Psychiatr Res. , vol.47 , pp. 1143-1149
    • Kishi, T.1    Iwata, N.2
  • 9
    • 0036750803 scopus 로고    scopus 로고
    • Amantadine treatment of psychotropic-induced weight gain in children and adolescents: Case series
    • Gracious BL, Krysiak TE, Youngstrom EA. Amantadine treatment of psychotropic-induced weight gain in children and adolescents: case series. J Child Adolesc Psychopharmacol. 2002;12:249-257.
    • (2002) J Child Adolesc Psychopharmacol. , vol.12 , pp. 249-257
    • Gracious, B.L.1    Krysiak, T.E.2    Youngstrom, E.A.3
  • 10
    • 0023154937 scopus 로고
    • Amantadine in the treatment of neuroendocrine side effects of neuroleptics
    • Correa N, Opler LA, Kay SR, et al. Amantadine in the treatment of neuroendocrine side effects of neuroleptics. J Clin Psychopharmacol. 1987;7:91-95.
    • (1987) J Clin Psychopharmacol. , vol.7 , pp. 91-95
    • Correa, N.1    Opler, L.A.2    Kay, S.R.3
  • 11
    • 0035063715 scopus 로고    scopus 로고
    • Effect of amantadine onweight gain during olanzapine treatment
    • FlorisM, Lejeune J, DeberdtW. Effect of amantadine onweight gain during olanzapine treatment. Eur Neuropsychopharmacol. 2001;11:181-182.
    • (2001) Eur Neuropsychopharmacol. , vol.11 , pp. 181-182
    • Floris, M.1    Lejeune, J.2    Deberdt, W.3
  • 12
    • 9644308090 scopus 로고    scopus 로고
    • Amantadine for weight gain associated with olanzapine treatment
    • Deberdt W, Winokur A, Cavazzoni PA, et al. Amantadine for weight gain associated with olanzapine treatment. Eur Neuropsychopharmacol. 2005; 15:13-21.
    • (2005) Eur Neuropsychopharmacol. , vol.15 , pp. 13-21
    • Deberdt, W.1    Winokur, A.2    Cavazzoni, P.A.3
  • 13
    • 24944539629 scopus 로고    scopus 로고
    • Double-blind, placebo-controlled investigation of amantadine for weight loss in subjects who gained weight with olanzapine
    • Graham KA, Gu H, Lieberman JA, et al. Double-blind, placebo-controlled investigation of amantadine for weight loss in subjects who gained weight with olanzapine. Am J Psychiatry. 2005;162:1744-1746.
    • (2005) Am J Psychiatry. , vol.162 , pp. 1744-1746
    • Graham, K.A.1    Gu, H.2    Lieberman, J.A.3
  • 14
    • 85018232981 scopus 로고    scopus 로고
    • A randomized, double-blind and controlled study of olanzapine plus amantadine in patients with first episode schizophrenia [In Chinese]
    • JiWJ, Jiang X, Chen HY, et al. A randomized, double-blind and controlled study of olanzapine plus amantadine in patients with first episode schizophrenia [In Chinese]. J Clin Psychiatry. 2014;24:1-3.
    • (2014) J Clin Psychiatry. , vol.24 , pp. 1-3
    • Ji, W.J.1    Jiang, X.2    Chen, H.Y.3
  • 15
    • 0023606101 scopus 로고
    • The positive and negative syndrome scale (PANSS) for schizophrenia
    • Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13: 261-276.
    • (1987) Schizophr Bull. , vol.13 , pp. 261-276
    • Kay, S.R.1    Fiszbein, A.2    Opler, L.A.3
  • 16
    • 0000503515 scopus 로고
    • The brief psychiatric rating scale
    • Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep. 1962;10:799-812.
    • (1962) Psychol Rep. , vol.10 , pp. 799-812
    • Overall, J.E.1    Gorham, D.R.2
  • 19
    • 0037098199 scopus 로고    scopus 로고
    • Quantifying heterogeneity in a meta-analysis
    • Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539-1558.
    • (2002) Stat Med. , vol.21 , pp. 1539-1558
    • Higgins, J.P.1    Thompson, S.G.2
  • 20
    • 78651415131 scopus 로고    scopus 로고
    • Effects of amantadine on tardive dyskinesia: A randomized, double-blind, placebo-controlled study
    • Pappa S, Tsouli S, Apostolou G, et al. Effects of amantadine on tardive dyskinesia: A randomized, double-blind, placebo-controlled study. Clin Neuropharmacol. 2010;33:271-275.
    • (2010) Clin Neuropharmacol. , vol.33 , pp. 271-275
    • Pappa, S.1    Tsouli, S.2    Apostolou, G.3
  • 21
    • 26944441259 scopus 로고    scopus 로고
    • A double-blind, cross-over comparison of the effects of amantadine or placebo on visuomotor and cognitive function in medicated schizophrenia patients
    • Silver H, Goodman C, Isakov V, et al. A double-blind, cross-over comparison of the effects of amantadine or placebo on visuomotor and cognitive function in medicated schizophrenia patients. Int Clin Psychopharmacol. 2005;20:319-326.
    • (2005) Int Clin Psychopharmacol. , vol.20 , pp. 319-326
    • Silver, H.1    Goodman, C.2    Isakov, V.3
  • 22
    • 0030922816 scopus 로고    scopus 로고
    • Bias in meta-analysis detected by a simple, graphical test
    • Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629-634.
    • (1997) BMJ. , vol.315 , pp. 629-634
    • Egger, M.1    Davey Smith, G.2    Schneider, M.3
  • 24
    • 79951955198 scopus 로고    scopus 로고
    • GRADE guidelines: 3. Rating the quality of evidence
    • Balshem H, Helfand M, Schünemann HJ, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol. 2011;64:401-406.
    • (2011) J Clin Epidemiol. , vol.64 , pp. 401-406
    • Balshem, H.1    Helfand, M.2    Schünemann, H.J.3
  • 25
    • 84974793861 scopus 로고    scopus 로고
    • Grading quality of evidence and strength of recommendations
    • Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recommendations. BMJ. 2004;328:1490.
    • (2004) BMJ. , vol.328 , pp. 1490
    • Atkins, D.1    Best, D.2    Briss, P.A.3
  • 26
    • 0029914622 scopus 로고    scopus 로고
    • Assessing the quality of reports of randomized clinical trials: Is blinding necessary?
    • Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996; 17:1-12.
    • (1996) Control Clin Trials. , vol.17 , pp. 1-12
    • Jadad, A.R.1    Moore, R.A.2    Carroll, D.3
  • 27
    • 0030995082 scopus 로고    scopus 로고
    • A controlled trial of amantadine hydrochloride and neuroleptics in the treatment of tardive dyskinesia
    • Angus S, Sugars J, Boltezar R, et al. A controlled trial of amantadine hydrochloride and neuroleptics in the treatment of tardive dyskinesia.JClin Psychopharmacol. 1997;17:88-91.
    • (1997) JClin Psychopharmacol. , vol.17 , pp. 88-91
    • Angus, S.1    Sugars, J.2    Boltezar, R.3
  • 28
    • 84942368577 scopus 로고    scopus 로고
    • Changes in verbal learning of patients with schizophrenia: Results from a randomized, double-blind, placebo-controlled trial of amantadine adjunctive to antipsychotics
    • Czepielewski LS, Sodré L, Souza AC, et al. Changes in verbal learning of patients with schizophrenia: results from a randomized, double-blind, placebo-controlled trial of amantadine adjunctive to antipsychotics. Schizophr Res. 2015;168:571-572.
    • (2015) Schizophr Res. , vol.168 , pp. 571-572
    • Czepielewski, L.S.1    Sodré, L.2    Souza, A.C.3
  • 29
    • 0030990693 scopus 로고    scopus 로고
    • Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents-preclinical studies
    • DanyszW, Parsons CG, Kornhuber J, et al. Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents-preclinical studies. Neurosci Biobehav Rev. 1997;21:455-468.
    • (1997) Neurosci Biobehav Rev. , vol.21 , pp. 455-468
    • Danysz, W.1    Parsons, C.G.2    Kornhuber, J.3
  • 30
    • 0028170903 scopus 로고
    • Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties
    • Kornhuber J,WellerM, Schoppmeyer K, et al. Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties. J Neural Transm Suppl. 1994;43:91-104.
    • (1994) J Neural Transm Suppl. , vol.43 , pp. 91-104
    • Kornhuber, J.1    Weller, M.2    Schoppmeyer, K.3
  • 31
    • 0030470687 scopus 로고    scopus 로고
    • Amantadine does not exacerbate positive symptoms in medicated, chronic schizophrenic patients: Evidence from a double-blind crossover study
    • Silver H,Geraisy N. Amantadine does not exacerbate positive symptoms in medicated, chronic schizophrenic patients: evidence from a double-blind crossover study. J Clin Psychopharmacol. 1996;16:463-464.
    • (1996) J Clin Psychopharmacol. , vol.16 , pp. 463-464
    • Silver, H.1    Geraisy, N.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.